Life Sciences Innovative Manufacturing Fund

Kanishka Narayan Excerpts

Wednesday 22nd October 2025 Commons Chamber

[Madam Deputy Speaker]

Well, quite. In that case, I call the Minister to move the motion. Is this your first time at the Dispatch Box, Minister?

[The Parliamentary Under-Secretary of State for Science, Innovation and Technology (Kanishka Narayan)]

Not quite.

[Madam Deputy Speaker]

Well, congratulations and welcome.

[The Parliamentary Under-Secretary of State for Science, Innovation and Technology (Kanishka Narayan)]

I beg to move,

That this House authorises the Secretary of State to undertake payments, by way of financial assistance under section 8 of the Industrial Development Act 1982, in excess of £30 million to any successful applicant to the Life Sciences Innovative Manufacturing Fund, launched on 30 October 2024, up to a cumulative total of £520 million.

Thank you for calling me on this none the less memorable occasion, Madam Deputy Speaker; it is the first occasion on which I seek the Chamber’s authority.

The life sciences sector is a jewel in the crown of our economy—a national asset that plays a unique role in both the health and the wealth of the United Kingdom. The sector drives jobs, investment and innovation right across the country, from cutting-edge research laboratories in Cheshire to—close to my heart—advanced manufacturing sites in south Wales. Life sciences manufacturing is the critical link between our world-class research and real-world patient benefit. It ensures that scientific breakthroughs translate into tangible improvements in care, while underpinning economic growth and strengthening the resilience of our NHS.

Yet despite the UK’s global leadership in many areas of life sciences manufacturing, we must acknowledge that, in recent years, growth in manufacturing sites and jobs has not kept pace with the expansion of the life sciences sector as a whole. That is why this summer the Government published the life sciences sector plan—a comprehensive strategy to ensure growth in all parts of the sector. The plan sets out the UK’s ambition to secure more life sciences foreign direct investment than any other European economy by 2030, behind only the US and China globally by 2035.

Central to that ambition is boosting manufacturing through delivery of the life sciences innovative manufacturing fund, one of six headline commitments in the sector plan. Launched last October, the fund demonstrates this Government’s commitment to the continued growth of our life sciences sector, with up to £520 million of funding available to support private sector capital investments until 2030.

[Jim Allister (North Antrim) (TUV)]

Northern Ireland has a vibrant life sciences manufacturing sector. I am looking to the Minister for an assurance relating to article 10 of the Windsor framework, which subjects Northern Ireland to EU state aid rules. Can the Minister assure us that there is no impediment arising therein that would impede successful applications to the fund from Northern Ireland manufacturers? That could also have a knock-on effect on GB, because if the goods produced are transported to Northern Ireland, they, too, come under the state aid rules. Has the Department examined that? What assurance can the Government give us on the protection against EU state aid rules for the fund?

[Kanishka Narayan]

The talent and ability of people in Northern Ireland are very much at the forefront of our minds, and we want to ensure that everything we are doing to support the life sciences sector is taking a whole-UK approach. I am very happy to write to the hon. and learned Member on his questions about Northern Irish eligibility.

[Robin Swann (South Antrim) (UUP)]

Will the Minister give way?

[Kanishka Narayan]

I will make some progress for now.

The life sciences innovative manufacturing fund directly supports two of the Government’s key missions: to kick-start economic growth and to build an NHS fit for the future. The scheme is projected to attract nearly £4 billion in private investment, creating more than 7,000 jobs and safeguarding more than 5,000 existing ones.

However, the scheme’s impact is not just economic. The pandemic proved that we cannot take our critical supply chains for granted, and supporting the onshoring of life sciences manufacturing through the fund is therefore critical to strengthening our national resilience and preparedness for future health emergencies.

[Robin Swann]

Will the Minister give way?

[Kanishka Narayan]

I will make some progress.

This week we announced the first two grant awards through the scheme, marking a major milestone in the fund’s roll-out. This will unlock substantial private investment, showcasing the UK’s appeal to valuable, globally mobile life sciences manufacturers. As delivery of the scheme progresses, we expect to announce more grant winners in the coming months. Each project supported through the grant will further strengthen health resilience and drive economic growth across all nations and regions in the UK.

[James Wild (North West Norfolk) (Con)]

Since the Minister has been talking about taxpayers’ money, I would be grateful if he could let us know what the minimum leverage is. For every pound of taxpayers’ money put in, what is the minimum that has to be put in by the private sector?

[Kanishka Narayan]

My understanding is that these are grant capital investments that the Government will be making, and I am sure we will be looking at the leverage at a whole-fund level. If there are particular requirements at an individual investment level, I am happy to write to the hon. Member on that particular point.

[Robin Swann]

Will the Minister give way?

[Kanishka Narayan]

I feel that, out of parity, I must give way to the hon. Member too.

[Robin Swann]

Third time lucky. I welcome the Minister’s announcement of the fund for life sciences with regard to the companies we have in North Antrim and South Antrim. Could the Minister also ensure that any research and development tax credits that companies can apply for are fully supported, utilised and brought forward at speed so that companies are able to utilise not just the fund but the tax credits that come through R&D as well?

[Kanishka Narayan]

I thank the hon. Member for his important point. I am happy to take a full look at the R&D tax credit system and how it will support our ambitions to back our private sector partners in both R&D and subsequent commercialisation.

The Government are clear that the life sciences innovative manufacturing fund is a strategic investment in our future. It is a vital step in delivering the Government’s commitment to supporting the UK’s life sciences sector and ensuring that our country remains at the forefront of the sector.

[Madam Deputy Speaker (Ms Nusrat Ghani)]

I call the shadow Secretary of State.

--- Later in debate ---

[Kanishka Narayan]

I want to be in your good books, Madam Deputy Speaker, so I will proceed at pace in answering some of the questions raised.

I first thank the Members on the shadow Front Benches and in particular the hon. Member for Hornchurch and Upminster (Julia Lopez). I was sad that her generous welcome to me was not extended to this particular announcement. In particular, I was sad that she did not welcome the fact that out of their Tory fiscal wreckage we have managed to get £520 million for the British life sciences sector, that out of the economic damage they did to this country we have still managed to secure over £1 billion in investment from Moderna in the British life sciences sector, and that out of what we inherited from the Tory context we have managed to secure over £1 billion from BioNTech. Right across the board, there is a picture of stability, good jobs in the life sciences and broader technology sectors, optimism and, above all, an energy shared across Government, the private sector and academia.

[Lincoln Jopp]

Will the Minister give way?

[Kanishka Narayan]

I must proceed because, as I said, I need to be in Madam Deputy Speaker’s good books.

A particular concern has been raised about VPAG, another part of a longer-standing legacy from a Tory Chancellor’s austerity rampage for the life sciences sector in this country. The Government’s position is very clear: we will always put patients and taxpayers first. This Government are open to working collaboratively with the pharmaceutical industry, which is exactly why we have put forward a generous and unprecedented offer worth approximately £1 billion over three years as part of a review of VPAG, which ultimately industry did not take a vote on.

We remain confident in the life sciences as a driver of both economic growth and better health outcomes and our door remains open to future engagement. I know that regular conversations go on and while I will not update Members on the shadow Front Benches on every single meeting the Secretary of State takes, I can assure them that she is involved in both the particular conversations around VPAG and more general engagement with the life sciences sector.

I particularly thank my hon. Friend the Member for Newcastle upon Tyne Central and West (Dame Chi Onwurah), whose depth of experience in engineering prior to this House and extensive experience in this House, in particular through leadership of the Science and Technology Committee, is one that I take considerable inspiration from.

[Lincoln Jopp]

Will the Minister give way?

[Kanishka Narayan]

I will make some progress for now. My hon. Friend raised a particular point around synthetic biology, which is very close to my heart because I think that Britain has a particular opportunity in the convergence of engineering, AI and life sciences, and we are keen on seizing that to its fullest extent.

On the three particular questions from my hon. Friend the Member for Newcastle upon Tyne Central and West, foremost of which was about the size of the funding available, I will say a couple of things: first, that this is the largest fund of this nature announced in the history of the UK Government, to my understanding, with capital grants worth £520 million altogether; and secondly, that it is but one part of the overall funding package across Government if one considers the investments across Innovate UK, UKRI, the British Business Bank and beyond. I hope that some of the assurances around VPAG have answered the particular question posed there, and on regional impact, I point out that the first two grants from the scheme were made out to firms in Birmingham and Keele. I hope that is a starting indicator of my long-term hope; we will certainly monitor it.

[Lincoln Jopp]

On that, will he give way?

[Kanishka Narayan]

I am afraid I will not; I believe I have been relatively generous in welcoming contributions from across the House. On the point of regional impact, in addition to the midlands, may I join the shadow Front Benchers in welcoming—they do so with laughter and amusement—the collective efforts of our entire Northern Irish contingent? I will take away the strong point about Northern Ireland’s strengths in the life sciences sector; it will be embedded on my mind.

I thank the hon. Member for South Cambridgeshire (Pippa Heylings) for South Cambridgeshire for talking about investments. The only thing I will say on some of the announcements is that they have to be taken in the context of the wider global context for those firms, MSD in particular.

[Lincoln Jopp]

On the point of global context, will he give way?

[Kanishka Narayan]

If the Member listens, he may feel that his point is addressed in my claims. In at least one of those cases, a pause, rather than a cancellation, was announced and in the other, there have been a series of announcements globally regarding thousands of jobs, not only in the UK but beyond. As I said, I hope that the two announcements I mentioned, by Moderna and BioNTech, will give us some assurance that the life sciences sector in the British context is firing on all cylinders with Government support.

Finally, I note with thanks the important point on national security and IP made by the hon. Member for Lagan Valley (Sorcha Eastwood). It is top of mind for me in ensuring that we are not just powering economic growth and not just jobs and good health for people across this country, but doing the first job of Government to protect our national security.

Question put and agreed to.

Resolved,

That this House authorises the Secretary of State to undertake payments, by way of financial assistance under section 8 of the Industrial Development Act 1982, in excess of £30 million to any successful applicant to the Life Sciences Innovative Manufacturing Fund, launched on 30 October 2024, up to a cumulative total of £520 million.